Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Abivax SA Sponsored ADR ( (ABVX) ) has issued an update.
On June 2, 2025, Abivax SA announced its financial results for the first quarter ending March 31, 2025. The company reported an increased operating loss of EUR 47.2 million, primarily due to higher research and development expenses related to its Crohn’s Disease clinical program and organizational growth. Despite a decrease in sales and marketing expenses, the net financial loss for the period was EUR 52.4 million, driven by interest expenses and foreign exchange losses. Abivax’s cash position decreased to EUR 103.6 million by the end of March 2025, with expectations to finance operations into the fourth quarter of 2025.
The most recent analyst rating on (ABVX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
Abivax SA’s stock score reflects significant financial challenges, with ongoing operational losses and high reliance on debt. Despite some revenue growth, the company’s financial stability is a concern. Technical analysis shows neutral momentum, with no strong buying or selling indicators. Valuation is weak due to negative earnings and no dividend yield, making it less attractive for traditional value investors. Overall, strategic improvements are necessary to enhance its financial and market position.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company based in France and the United States, focusing on developing therapeutics that utilize the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company’s lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis.
Average Trading Volume: 218,372
Technical Sentiment Signal: Sell
Current Market Cap: $380.8M
Learn more about ABVX stock on TipRanks’ Stock Analysis page.